Allena Competitors

Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Allena Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Allena Pharmaceuticals in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
0.010.1118.34
Details
Intrinsic
Valuation
LowReal ValueHigh
0.071.3619.59
Details
Naive
Forecast
LowNext ValueHigh
0.0033940.1718.40
Details
4 Analysts
Consensus
LowTarget PriceHigh
1.255.0611.00
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Allena Pharmaceuticals. Your research has to be compared to or analyzed against Allena Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Allena Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Allena Pharmaceuticals.

Allena Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Allena Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Allena and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Allena Pharmaceuticals does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Allena Pharmaceuticals Competition Risk-Adjusted Indicators

Nowadays, there is a big difference between Allena Pharmaceuticals stock performing well and Allena Pharmaceuticals company doing well compared to the competition. There are way too many exceptions to the normal that investors can tell for sure what's good or bad unless they analyze Allena Pharmaceuticals' multiple risk-adjusted performance indicators. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean
Deviation
Jensen
Alpha
Sortino
Ratio
Treynor
Ratio
Semi
Deviation
Information
Ratio
Expected
Shortfall
Potential
Upside
Value
At Risk
Maximum
Drawdown
AA 2.97 (0.16)  0.00 (0.01)  0.00 (0.0262)  0.00  5.50 (5.50)  17.64 
VZ 0.92 (0.10)  0.00 (0.22)  0.00 (0.11)  0.00  1.79 (2.43)  10.04 
KO 0.99 (0.05) (0.04)  0.01  1.66 (0.0472) (0.95)  1.87 (1.96)  8.84 
CVX 1.75 (0.04) (0.02)  0.02  2.34 (0.0222) (1.68)  3.06 (4.35)  11.62 
T 0.79 (0.08)  0.00  0.88  0.00 (0.14)  0.00  1.69 (1.63)  7.50 
CSCO 1.37 (0.14)  0.00 (0.06)  0.00 (0.06)  0.00  2.73 (1.76)  17.00 
MCD 0.94  0.06  0.03  0.16  1.09  0.0265 (1.05)  2.22 (1.55)  4.73 
HD 1.16 (0.05)  0.00  0.38  0.00 (0.09)  0.00  2.29 (2.48)  7.12 
GE 1.60  0.06  0.03  0.12  1.99  0.0349 (1.61)  3.33 (3.32)  8.85 

Cross Equities Net Income Analysis

Compare Allena Pharmaceuticals and related stocks such as Alcoa Corp, Verizon Communications, Coca-Cola, Chevron Corp, ATT Inc, Cisco Systems, McDonalds Corp, Home Depot, and General Electric Net Income Over Time
Select Fundamental

2010201120122013201420152016201720182019202020212022
AA(2.9 B)(2.9 B)(2.9 B)(2.9 B)(256 M)(863 M)(400 M)279 M250 M(1.1 B)(170 M)429 M462.9 M
VZ2.5 B2.4 B875 M11.5 B9.6 B17.9 B13.1 B30.1 B15.5 B19.3 B17.8 B22.1 B23.8 B
KO8.6 B8.6 BB8.6 B7.1 B7.4 B6.5 B1.2 B6.4 B8.9 B7.7 B9.8 B8.3 B
CVX26.9 B26.9 B26.2 B21.4 B19.2 B4.6 B(497 M)9.2 B14.8 B2.9 B(5.5 B)15.6 B13.4 B
T19.9 B3.9 B7.3 B18.2 B6.2 B13.3 B13 B29.4 B19.4 B13.9 B(5.2 B)20.1 B16.2 B
CSCOBBBBB11.2 B11.2 B11.2 B11.2 B11.2 B10.6 B12.2 B11.5 B
MCD5.5 B5.5 B5.5 B5.6 B4.8 B4.5 B4.7 B5.2 B5.9 BB4.7 B7.5 B7.1 B
HD6.3 B6.3 B6.3 B6.3 B6.3 B11.2 B11.2 B11.2 B11.2 B11.2 B16.4 B16.4 B15.4 B
GE14.2 B14.2 B13.6 B13.1 B15.2 B(6.1 B)7.5 B(8.5 B)(22.4 B)(5 B)5.7 B(6.5 B)(6.7 B)

Allena Pharmaceuticals and related stocks such as Alcoa Corp, Verizon Communications, Coca-Cola, Chevron Corp, ATT Inc, Cisco Systems, McDonalds Corp, Home Depot, and General Electric Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Allena Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Allena Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. The portion of profit or loss for the period; net of income taxes; which is attributable to the parent after the deduction of Net Income Available to Non-controlling Interests from Consolidated Income; and before the deduction of Preferred Dividends.

Allena Pharmaceuticals Competitive Analysis

The better you understand Allena Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Allena Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Allena Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ALNAAAVZKOCVXTCSCOMCDHDGE
 7.69 
 0.12 
Allena
 0.96 
 52.76 
Alcoa
 0.83 
 45.15 
Verizon
 0.76 
 63.70 
Coca Cola
 0.14 
 159.85 
Chevron
 1.27 
 18.27 
ATT
 1.55 
 46.61 
Cisco
 1.12 
 262.18 
McDonalds
 1.35 
 314.89 
Home Depot
 1.31 
 79.93 
General
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Stock Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Trade Advice
(90 Days Macroaxis Advice)
Number of Shares Shorted
Shares Owned by Insiders
Current Ratio
Profit Margin
EBITDA
Current Valuation
Cash Flow from Operations
Operating Margin
Retained Earnings
Current Asset
Five Year Return
Beta
Price to Book
Shares Outstanding
Total Debt
Return On Equity
Price to Earning
Z Score
Shares Owned by Institutions
Return On Asset
Book Value Per Share
Cash and Equivalents
Current Liabilities
Price to Earnings To Growth
Total Asset
Short Ratio
Last Dividend Paid
Market Capitalization
Price to Sales
Cash per Share
Net Income
Earnings Per Share
Debt to Equity
Revenue
Working Capital
Gross Profit
Day Typical Price
Accumulation Distribution
Market Facilitation Index
Daily Balance Of Power
Rate Of Daily Change
Day Median Price
Price Action Indicator
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Allena Pharmaceuticals Competition Performance Charts

Complement your Allena Pharmaceuticals position

In addition to having Allena Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Baby Boomer Prospects Thematic Idea Now

Baby Boomer Prospects
Baby Boomer Prospects Theme
Equities with large market capitalization that account for significant contribution to overall economic growth especially within dividend-paying instruments and stocks from healthcare and financial sectors. The Baby Boomer Prospects theme has 97 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Baby Boomer Prospects Theme or any other thematic opportunities.
View All  Next Launch
Please continue to Allena Pharmaceuticals Correlation with its peers. Note that the Allena Pharmaceuticals information on this page should be used as a complementary analysis to other Allena Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for Allena Stock analysis

When running Allena Pharmaceuticals price analysis, check to measure Allena Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allena Pharmaceuticals is operating at the current time. Most of Allena Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Allena Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Allena Pharmaceuticals' price. Additionally, you may evaluate how the addition of Allena Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Is Allena Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allena Pharmaceuticals. If investors know Allena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allena Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
13.1 M
Return On Assets
-0.96
Return On Equity
-2.78
The market value of Allena Pharmaceuticals is measured differently than its book value, which is the value of Allena that is recorded on the company's balance sheet. Investors also form their own opinion of Allena Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Allena Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allena Pharmaceuticals' market value can be influenced by many factors that don't directly affect Allena Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allena Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Allena Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allena Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ALNA
 Stock
  

USD 0.12  0.01  7.69%   

Allena Pharmaceuticals competes with Alcoa Corp, Verizon Communications, Coca Cola, Chevron Corp, and ATT; as well as few others. The company conducts business under Healthcare sector and is part of Biotechnology industry. Analyzing Allena Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Allena Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Allena Pharmaceuticals competition on your existing holdings. Please continue to Allena Pharmaceuticals Correlation with its peers.
  
As of August 14, 2022, Return on Average Assets is expected to decline to -1.34. In addition to that, Return on Average Equity is expected to decline to -2.48. Allena Pharmaceuticals Total Assets are projected to decrease significantly based on the last few years of reporting. The past year's Total Assets were at 34.76 Million. The current year Current Assets is expected to grow to about 40.4 M, whereas Assets Non Current are forecasted to decline to about 1.4 M.